FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

By M. Cohen, Y. Shen, P. Keegan, R. Pazdur. The Oncologist, 2009

669 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/04c6e32f06f34188b9b19110ddd80654ef06d123

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Lathia
2. Jeremy N. Rich

In Genetics

1. J. Lathia
2. Jeremy N. Rich

In Oncology

1. J. Lathia
2. Jeremy N. Rich

Citations in the corpus

• Cancer stem cells in glioblastoma (2015, methodology): “The humanized monoclonal antibody bevacizumab was developed to target VEGF to inhibit angiogenesis and has been used to treat recurrent GBM (Cohen et al. 2009).”